Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Expert Opinion / Cases · February 01, 2022

De Novo Metastatic Castration Sensitive Prostate Cancer in a 73-Year-Old Black Patient

Written by
Pedro C. Barata MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Charles Maack

    Feb 04, 2022

    2 - radium223 (with the option to remain on enzalutamide) 

  • Waleed Ragab

    Feb 04, 2022

    4 Docetaxel

  • Rham Zaki

    Mar 19, 2022

    Radium 223

  • Prasanta Kumar Pradhan

    Apr 02, 2022

    2.Radium-223 and continue on enzalutamide

  • Nov 30, 2023

    Pending Moderator approval.

Further Reading